Physician profile
Roger Wayne Farris
NPI 1902491558
$2,427.14
in general payments reported to CMS, 2019-2025
27 companies · $888 in 2025
The $888 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $34.05 · 2022: $471 · 2023: $436 · 2024: $598 · 2025: $888.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,907 · Education: $15.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,907.32 |
| Education | $15.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $332.84 | 2021-2025 | Rexulti |
| Abbvie INC. | $283.65 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $267.35 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $231.31 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $193.93 | 2022-2025 | Caplyta |
| Exact Sciences Corporation | $135.97 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $109.46 | 2022-2023 | |
| Mylan Specialty L.P. | $99.02 | 2022-2023 | Yupelri |
| Axsome Therapeutics, INC. | $87.12 | 2024-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $71.89 | 2025 | Fanapt |
| Almatica Pharma LLC | $71.79 | 2024-2025 | Loreev Xr |
| Lilly USA, LLC | $71.64 | 2022-2025 | Mounjaro, Zepbound |
| Verona Pharma, INC. | $58.80 | 2025 | Ohtuvayre |
| Glaxosmithkline, LLC. | $55.91 | 2022-2024 | Trelegy Ellipta |
| Biohaven Pharmaceutical Holding Company LTD. | $47.72 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $44.02 | 2022-2023 | Dexcom G6 Transmitter |
| Electromed, INC. | $42.75 | 2024-2025 | Smartvest |
| Pfizer INC. | $42.26 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $40.18 | 2022-2025 | |
| Vertex Pharmaceuticals Incorporated | $23.72 | 2024 | |
| Alexion Pharmaceuticals, INC. | $22.71 | 2024 | Ultomiris |
| Astellas Pharma US INC | $18.43 | 2025 | Veozah |
| Sanofi Pasteur INC. | $17.94 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.75 | 2023 | |
| Supernus Pharmaceuticals, INC. | $15.04 | 2025 | |
| Philips North America LLC | $13.58 | 2023 | |
| Cequr Corporation | $11.36 | 2025 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Farris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.